home / stock / fphaf / fphaf short
Short Information | Faron Pharmaceuticals Oy (OTCMKTS:FPHAF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 12,079 |
Total Actual Volume | 15,979 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 7 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 604 |
Average Short Percentage | 35.72% |
Is there a FPHAF Short Squeeze or Breakout about to happen?
See the FPHAF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
09-07-2021 | $5 | $4.7 | $5 | $4.7 | 3,100 | 100 | 3.23% |
08-19-2021 | $5.25 | $5.25 | $5.25 | $5.25 | 4,900 | 4,900 | 100% |
07-14-2021 | $5.5 | $5.5 | $5.5 | $5.5 | 100 | 100 | 100% |
06-22-2021 | $5.4999 | $5.4999 | $5.4999 | $5.4999 | 399 | 399 | 100% |
06-17-2021 | $5.5 | $5.5 | $5.5 | $5.5 | 100 | 100 | 100% |
01-29-2021 | $5.4 | $5.5 | $5.5 | $5.4 | 2,466 | 2,466 | 100% |
01-28-2021 | $5.3 | $5.3 | $5.3 | $5.3 | 900 | 900 | 100% |
01-25-2021 | $5.51 | $5.6 | $5.6 | $5.51 | 1,014 | 114 | 11.24% |
04-28-2020 | $4.83 | $4.75 | $4.83 | $4.75 | 3,000 | 3,000 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Faron Pharmaceuticals Oy Company Name:
FPHAF Stock Symbol:
OTCMKTS Market:
Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients. 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up. While data do not yet all...
(NewsDirect) Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndr...
TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvi...